CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 17 enrolled
Drug / intervention
Omega 3 fatty acids +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00467818
NCT00467818N/ACompleted

Omega 3 Fatty Acids in the Treatment of Children With Autism Spectrum Disorders

University of Medicine and Dentistry of New Jersey·interventional·Posted May 1, 2007·Updated Jan 26, 2021

In Brief

A clinical study evaluating Omega 3 fatty acids and Placebo for Autism. Completed, enrolled 17 participants across 1 site.

Detailed Summary

Published studies on omega 3 fatty acids in the treatment of bipolar disorder and schizophrenia have shown reductions in time to recurrence, a decrease in the positive and negative symptoms of schizophrenia, and improvements in Clinical Global Impression Scale, Young Mania Rating Scale, and HAM-D scores. The following are the hypotheses: * Omega 3 fatty acids will be superior to placebo in the acute treatment of global autism. * Omega 3 fatty acids will be superior to placebo in improving aggression and irritability associated with autism. * Omega 3 fatty acids will be superior to placebo in improving functional ability.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAutism
CountriesUnited States

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 1, 2007
Enrollment StartJan 1, 2007
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 19.2 years ago

Interventions

Omega 3 fatty acidsdrug

The study will start with low doses and based on the weight of the individual the dosage will be increased biweekly.

Placeboother

Same dosage as that of omega 3 fatty acids